SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+4.89%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$5.16B
AUM Growth
+$5.16B
(-12%)
Cap. Flow
-$795M
Cap. Flow
% of AUM
-15.4%
Top 10 Holdings %
Top 10 Hldgs %
43.21%
Holding
125
New
19
Increased
28
Reduced
23
Closed
30
Top Buys
| 1 |
Microsoft
MSFT
|
$291M |
| 2 |
Monster Beverage
MNST
|
$110M |
| 3 |
Hilton Worldwide
HLT
|
$93.4M |
| 4 |
Marriott International Class A Common Stock
MAR
|
$81.6M |
| 5 |
Deckers Outdoor
DECK
|
$79.2M |
Top Sells
| 1 |
Twilio
TWLO
|
$165M |
| 2 |
Mastercard
MA
|
$152M |
| 3 |
Adobe
ADBE
|
$137M |
| 4 |
PLAN
Anaplan, Inc.
PLAN
|
$132M |
| 5 |
UnitedHealth
UNH
|
$130M |
Sector Composition
| 1 | Healthcare | 35.27% |
| 2 | Consumer Discretionary | 21.54% |
| 3 | Technology | 17.68% |
| 4 | Industrials | 15.65% |
| 5 | Consumer Staples | 5.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Danaher
DHR
$147B
| $72.4M | 1.4% |
+220,200
| New | +$72.4M |
|
|
XYZ
27
Block, Inc.
XYZ
$48.5B
| $69.4M | 1.34% |
429,984
+127,054
| +42% | +$20.5M |
|
|
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $65.5M | 1.27% |
1,251,946
| – | – |
|
29
TE Connectivity
TEL
$61B
| $61.7M | 1.2% |
382,623
-221,254
| -37% | -$35.7M |
|
30
Natera
NTRA
$23.1B
| $59.4M | 1.15% |
636,160
-111,060
| -15% | -$10.4M |
|
|
MRTX
31
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $59.1M | 1.14% |
402,789
+211,481
| +111% | +$31M |
|
32
Rivian
RIVN
$16.5B
| $52.7M | 1.02% |
+507,830
| New | +$52.7M |
|
33
Kura Oncology
KURA
$686M
| $50M | 0.97% |
3,572,419
+1,112,217
| +45% | +$15.6M |
|
34
Copart
CPRT
$47.2B
| $46.2M | 0.9% |
305,000
-567,764
| -65% | -$86.1M |
|
35
Fulcrum Therapeutics
FULC
$351M
| $42M | 0.81% |
2,375,571
+433,602
| +22% | +$7.67M |
|
36
Ultragenyx Pharmaceutical
RARE
$2.89B
| $40.8M | 0.79% |
+485,242
| New | +$40.8M |
|
37
Agios Pharmaceuticals
AGIO
$2.19B
| $38.7M | 0.75% |
1,177,374
-134,374
| -10% | -$4.42M |
|
38
Sutro Biopharma
STRO
$72.7M
| $36.3M | 0.7% |
2,437,795
+204,100
| +9% | +$3.04M |
|
39
Warby Parker
WRBY
$3.2B
| $34.1M | 0.66% |
733,402
-266,598
| -27% | -$12.4M |
|
40
KBR
KBR
$6.5B
| $32.6M | 0.63% |
685,500
-2,297,877
| -77% | -$109M |
|
|
MRNS
41
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $31.3M | 0.61% |
2,638,775
+441,349
| +20% | +$5.24M |
|
42
EyePoint Pharmaceuticals
EYPT
$797M
| $30.8M | 0.6% |
2,519,700
+815,111
| +48% | +$9.98M |
|
43
Insmed
INSM
$28.8B
| $29.5M | 0.57% |
1,081,532
+82,800
| +8% | +$2.26M |
|
44
Etsy
ETSY
$5.25B
| $26.7M | 0.52% |
+122,158
| New | +$26.7M |
|
45
Marqeta
MQ
$2.86B
| $25.2M | 0.49% |
+1,467,368
| New | +$25.2M |
|
46
Kezar Life Sciences
KZR
$28.9M
| $23.6M | 0.46% |
1,409,956
| – | – |
|
47
KalVista Pharmaceuticals
KALV
$678M
| $23.1M | 0.45% |
1,746,300
+203,016
| +13% | +$2.69M |
|
|
ARNA
48
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $22.8M | 0.44% |
245,800
-261,288
| -52% | -$24.3M |
|
49
Heron Therapeutics
HRTX
$207M
| $22.7M | 0.44% |
2,486,340
+995,900
| +67% | +$9.09M |
|
50
Xenon Pharmaceuticals
XENE
$2.98B
| $21.6M | 0.42% |
692,000
-466,961
| -40% | -$14.6M |
|